710 related articles for article (PubMed ID: 24086952)
21. Pomalidomide for multiple myeloma.
Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
[TBL] [Abstract][Full Text] [Related]
22. Daratumumab granted breakthrough drug status.
Laubach JP; Tai YT; Richardson PG; Anderson KC
Expert Opin Investig Drugs; 2014 Apr; 23(4):445-52. PubMed ID: 24555809
[TBL] [Abstract][Full Text] [Related]
23. Salvage therapy of multiple myeloma: the new generation drugs.
Romano A; Conticello C; Cavalli M; Vetro C; Di Raimondo C; Di Martina V; Schinocca E; La Fauci A; Parrinello NL; Chiarenza A; Di Raimondo F
Biomed Res Int; 2014; 2014():456037. PubMed ID: 24967371
[TBL] [Abstract][Full Text] [Related]
24. Recent advances in the treatment of Multiple Myeloma.
Yasui H; Hideshima T; Richardson PG; Anderson KC
Curr Pharm Biotechnol; 2006 Oct; 7(5):381-93. PubMed ID: 17076653
[TBL] [Abstract][Full Text] [Related]
25. Novel drug combinations for the management of relapsed/refractory multiple myeloma.
Usmani SZ; Lonial S
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S71-7. PubMed ID: 25486960
[TBL] [Abstract][Full Text] [Related]
26. Immunomodulation as a therapeutic strategy in the treatment of multiple myeloma.
Mitsiades CS; Chen-Kiang S
Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S5-13. PubMed ID: 23806982
[TBL] [Abstract][Full Text] [Related]
27. New insights into therapeutic targets in myeloma.
Anderson KC
Hematology Am Soc Hematol Educ Program; 2011; 2011():184-90. PubMed ID: 22160032
[TBL] [Abstract][Full Text] [Related]
28. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
Thompson JL
Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
[TBL] [Abstract][Full Text] [Related]
29. Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
Nijhof IS; Groen RW; Noort WA; van Kessel B; de Jong-Korlaar R; Bakker J; van Bueren JJ; Parren PW; Lokhorst HM; van de Donk NW; Martens AC; Mutis T
Clin Cancer Res; 2015 Jun; 21(12):2802-10. PubMed ID: 25398450
[TBL] [Abstract][Full Text] [Related]
30. [New drugs in the treatment of multiple myeloma].
Oriol A; Motlló C
Med Clin (Barc); 2014 Sep; 143(6):268-74. PubMed ID: 24342015
[TBL] [Abstract][Full Text] [Related]
31. Relapsed/Refractory multiple myeloma: defining refractory disease and identifying strategies to overcome resistance.
Siegel DS
Semin Hematol; 2012 Jul; 49 Suppl 1():S3-15. PubMed ID: 22727390
[TBL] [Abstract][Full Text] [Related]
32. Research progress in proteasome inhibitor resistance to multiple myeloma.
Wu J; Liu J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 46(8):900-908. PubMed ID: 34565737
[TBL] [Abstract][Full Text] [Related]
33. Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.
Bringhen S; Gay F; Donato F; Troia R; Mina R; Palumbo A
Expert Opin Investig Drugs; 2014 Sep; 23(9):1193-209. PubMed ID: 24905450
[TBL] [Abstract][Full Text] [Related]
34. [Molecular targeting agents for multiple myeloma].
Fujii S; Abe M
Nihon Rinsho; 2012 Nov; 70 Suppl 8():518-23. PubMed ID: 23513894
[No Abstract] [Full Text] [Related]
35. Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.
Richardson PG; Mark TM; Lacy MQ
Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S36-44. PubMed ID: 23786844
[TBL] [Abstract][Full Text] [Related]
36. Proteasome inhibitors in the treatment of multiple myeloma.
McBride A; Ryan PY
Expert Rev Anticancer Ther; 2013 Mar; 13(3):339-58. PubMed ID: 23477520
[TBL] [Abstract][Full Text] [Related]
37. Novel therapies for relapsed myeloma.
Stewart AK
Hematology Am Soc Hematol Educ Program; 2009; ():578-86. PubMed ID: 20008242
[TBL] [Abstract][Full Text] [Related]
38. [Daratumumab--breakthrough drug in multiple myeloma therapy].
Jurczyszyn A; Kosmaczewska A; Skotnicki AB
Postepy Hig Med Dosw (Online); 2014 Nov; 68():1352-60. PubMed ID: 25531698
[TBL] [Abstract][Full Text] [Related]
39. Role of carfilzomib in the treatment of multiple myeloma.
Khan RZ; Badros A
Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230
[TBL] [Abstract][Full Text] [Related]
40. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
Steele JM
J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
